INTRABIO
DEAD

Serial Number

79232153

Owner

IntraBio Ltd

Filing Date

Feb 14, 2018

Add to watchlist:

No watchlists yet
View on USPTO

INTRABIO Trademark

Serial Number: 79232153

INTRABIO is a trademark filed by IntraBio Ltd on February 14, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

IntraBio Ltd (3 trademarks)

Summit House 170, Finchley Road
London NW36BP , GB

Entity Type: 99

Trademark Details

Filing Date

February 14, 2018

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations; pharmaceutical preparations for activating cellular function; pharmaceutical preparations for the prevention of diseases of the nervous system; pharmaceutical preparations for treating sensory organ disorders; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative diseases; pharmaceutical preparations for use in the prevention and treatment of neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; drugs for medical purposes; drugs for medical purposes, namely, the prevention and treatment of neurodegenerative diseases; drugs for medical purposes, namely, the prevention and treatment of neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; reagents for use in medical genetic testing; diagnostic reagents for medical laboratory use; diagnostic reagents for medical laboratory use, namely, use in the detection and identification of neurodegenerative diseases; diagnostic reagents for medical laboratory use, namely, use in the detection and identification of neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; amino acid preparations for medical purposes; amino acid preparations for pharmaceutical use

Scientific and technological services and research and design relating thereto; industrial analysis and research services; scientific and technological services and research in the field of neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; industrial analysis and research services related to neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy, design and development of computer hardware and software related to assays; clinical trials; conducting clinical trials for pharmaceutical products; conducting clinical trials for neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; medical laboratories for research related to neurodegenerative diseases, namely, lysosomal storage disorders, niemann-pick disease, alzheimer's disease, parkinson's disease, prion disease, motor neurone disease, huntington's disease, spinocerebellar ataxia and spinal muscular atrophy; providing information about the results of clinical trials for pharmaceutical products; clinical research; medical laboratories; research relating to molecular sciences; medical research; genetic research; research in the field of gene therapy; biopharmaceutical research for development of targeted therapies for use in the treatment of carcinomas and neurodegenerative diseases; scientific, biochemical, research and development services in the field of neurodegenerative diseases; providing scientific information in the field of medical disorders and their treatment; pharmaceutical drug development services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Jan 31, 2020 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Jan 10, 2020 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jan 10, 2020 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Nov 8, 2019 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Oct 23, 2019 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Oct 23, 2019 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Jan 11, 2019 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jan 10, 2019 ABN2
REFUSAL PROCESSED BY IB
Jun 30, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Jun 14, 2018 RFCS
REFUSAL PROCESSED BY MPU
Jun 14, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jun 7, 2018 RFCR
NON-FINAL ACTION WRITTEN
Jun 6, 2018 CNRT
ASSIGNED TO EXAMINER
May 30, 2018 DOCK
APPLICATION FILING RECEIPT MAILED
May 25, 2018 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 21, 2018 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
May 17, 2018 REPR